Daily Archives: April 18, 2011

Updated: FEM-PrEP HIV prevention study halted

By on .

FHI issued a statement Monday morning announcing that the FEM-PrEP trial – looking at once-daily administration of the antiretroviral drug Truvada (emtricitabine and tenofovir) versus a placebo among high-risk heterosexual, HIV-negative women for preventing HIV infection – has been halted due to inability to determine effectiveness.

**Update: On a conference call convened by AVAC Tuesday, FHI representatives explained that self-reported adherence to the study drug was approximately 95 percent, excluding external factors such as stopping medication due to pregnancy. Trial investigators have blood specimens from partipants at certain intervals during the trial that they are testing for drug levels. Results from those tests will be reported in the coming months.